

# GRB10 (phospho Tyr67) Polyclonal Antibody

Catalog # AP67489

### **Product Information**

Application WB, IHC-P, IF
Primary Accession

Reactivity Human

Host Rabbit

Clonality Polyclonal

Calculated MW 67231

#### **Additional Information**

**Gene ID** 2887

Other Names GRB10; GRBIR; KIAA0207; Growth factor receptor-bound protein 10; GRB10

adapter protein; Insulin receptor-binding protein Grb-IR

Dilution WB~Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300.

Immunofluorescence: 1/200 - 1/1000. ELISA: 1/20000. Not yet tested in other applications. IHC-P~~Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/20000. Not yet

tested in other applications. IF~~1:50~200

Format Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium

azide.

Storage Conditions -20°C

#### **Protein Information**

Name GRB10

**Synonyms** GRBIR, KIAA0207

**Function** Adapter protein which modulates coupling of a number of cell surface

receptor kinases with specific signaling pathways. Binds to, and suppress signals from, activated receptors tyrosine kinases, including the insulin (INSR) and insulin-like growth factor (IGF1R) receptors. The inhibitory effect can be achieved by 2 mechanisms: interference with the signaling pathway and increased receptor degradation. Delays and reduces AKT1 phosphorylation in response to insulin stimulation. Blocks association between INSR and IRS1

and IRS2 and prevents insulin-stimulated IRS1 and IRS2 tyrosine

phosphorylation. Recruits NEDD4 to IGF1R, leading to IGF1R ubiquitination, increased internalization and degradation by both the proteasomal and lysosomal pathways. May play a role in mediating insulin-stimulated ubiquitination of INSR, leading to proteasomal degradation. Negatively

regulates Wnt signaling by interacting with LRP6 intracellular portion and interfering with the binding of AXIN1 to LRP6. Positive regulator of the KDR/VEGFR-2 signaling pathway. May inhibit NEDD4-mediated degradation of KDR/VEGFR-2.

Cytoplasm. Note=When complexed with NEDD4 and IGF1R, follows IGF1R

internalization, remaining associated with early endosomes. Uncouples from IGF1R-containing endosomes before the sorting of the receptor to the

lysosomal compartment (By similarity).


**Tissue Location** Widely expressed in fetal and adult tissues, including fetal and postnatal liver,

lung, kidney, skeletal muscle, heart, spleen, skin and brain.


# **Background**

Adapter protein which modulates coupling of a number of cell surface receptor kinases with specific signaling pathways. Binds to, and suppress signals from, activated receptors tyrosine kinases, including the insulin (INSR) and insulin-like growth factor (IGF1R) receptors. The inhibitory effect can be achieved by 2 mechanisms: interference with the signaling pathway and increased receptor degradation. Delays and reduces AKT1 phosphorylation in response to insulin stimulation. Blocks association between INSR and IRS1 and IRS2 and prevents insulin- stimulated IRS1 and IRS2 tyrosine phosphorylation. Recruits NEDD4 to IGF1R, leading to IGF1R ubiquitination, increased internalization and degradation by both the proteasomal and lysosomal pathways. May play a role in mediating insulin- stimulated ubiquitination of INSR, leading to proteasomal degradation. Negatively regulates Wnt signaling by interacting with LRP6 intracellular portion and interfering with the binding of AXIN1 to LRP6. Positive regulator of the KDR/VEGFR-2 signaling pathway. May inhibit NEDD4-mediated degradation of KDR/VEGFR-2.

## **Images**



Western Blot analysis of COLO cells using Phospho-GRB10 (Y67) Polyclonal Antibody



Immunohistochemical analysis of paraffin-embedded Human brain. Antibody was diluted at 1:100(4°,overnight). High-pressure and temperature Tris-EDTA,pH8.0 was used for antigen retrieval. Negetive contrl (right) obtaned from antibody was pre-absorbed by immunogen peptide.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.